ADAA Conference - Boston (April 11-14) 2024
Scientific Research Symposia, Clinical Practice Symposium, & Treatment Sessions
Scientific Research Symposiums (SRS) + −
Intracranial Approaches to Characterizing and Treating Depression
Kelly Bijanki, PhD
Interventional Psychiatry: The Time is Now
Nolan Williams, MD
Translational Brain Circuit Engineering to Treat Mood & Anxiety Disorders
Alik Widge, MD, PHD
Clinical Practice Symposium (CPS) + −
Affirmative Mental Health Care for Transgender and Gender Diverse Youth: A Clinical Guide
Aron Janssen, MD and Scott Leibowitz, MD
New Vistas in the Treatment of Depression Symposia + −
Ketamine and Psychedelics - Where are we now?
Sanjay Mathew, MD
Sanjay J. Mathew, M.D. is the Marjorie Bintliff Johnson and Raleigh White Johnson, Jr. Vice Chair for Research and Professor in the Menninger Department of Psychiatry & Behavioral Sciences at Baylor College of Medicine. He is also a staff psychiatrist at the Michael E. Debakey VA Medical Center (MEDVAMC) in Houston, Texas. He graduated from Dartmouth College and Baylor College of Medicine, and trained in psychiatry at Columbia University and the New York State Psychiatric Institute, where he also completed a NIH-funded research fellowship in affective and anxiety disorders. Dr. Mathew began his faculty career at the Icahn School of Medicine at Mount Sinai where he co-founded and directed the Mood & Anxiety Disorders Program. In 2010, Dr. Mathew was recruited back to his hometown of Houston to direct Baylor’s Mood & Anxiety Disorders Program. His research program focuses on developing novel therapies for patients with treatment-resistant mood and anxiety disorders and PTSD, with a particular focus on rapid-acting glutamate-modulating agents.
Dr. Mathew’s research program has been funded by NIMH, Department of Veterans Affairs, Patient-Centered Outcomes Research Institute (PCORI), and industry in the areas of experimental therapeutics and pathophysiology of treatment-resistant depression, suicide, and PTSD. He has authored or co-authored over 130 manuscripts and book chapters, and serves on the editorial board of several journals. In addition to his long involvement with ADAA including serving as Chair of the Program Committee (2017-2018), Dr. Mathew is a member of the American College of Neuropsychopharmacology, and board member of the American Society of Clinical Psychopharmacology. An active clinician and teacher, Dr. Mathew has been selected by his peers as a “Best Doctor” every year since 2011, and has received awards for his teaching of psychopharmacology.
Next-Generation Strategies to Refine and Optimize DBS for Depression.
Helen Mayberg, MD
Deep Brain Stimulation is an experimental treatment for intractable depression. The availability of implanted sensing systems combined with precise image-guided targeting and new machine learning analytic strategies provide new tools for treatment optimization and mechanistic perspectives on the trajectory and sustainability of DBS effects. Further use of computer vision to assess naturalistic face and body movements offers new opportunities to link first-person experiences to brain and behavioral biomarkers that can reliably monitor and guide DBS management.
Helen Mayberg, MD is Professor of Neurology, Neurosurgery, Psychiatry and Neuroscience, and the Mount Sinai Professor in Neurotherapeutics at the Icahn School of Medicine where she serves as founding Director of the Nash Family Center for Advanced Circuit Therapeutics. Dr. Mayberg trained in Neurology at Columbia's Neurological Institute in New York, followed by a research fellowship in nuclear medicine at Johns Hopkins. She is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences and the National Academy of Inventors among other honors. Over her career, she and her colleagues have characterized neural systems mediating major depression and its recovery, defined imaging-based illness subtypes to optimize treatment selection and introduced the first use of deep brain stimulation for treatment resistant patients.
Unmet Needs in the Treatment of Depression
Charles B. Nemeroff, MD, PhD
Charles B. Nemeroff is currently the Professor and Chair, Department of Psychiatry and Director, Institute for Early Life Adversity Research. Previously, Dr. Nemeroff was the Leonard M. Miller Professor and Chairman of the Department of Psychiatry and Behavioral Sciences, and Clinical Director of the Center on Aging at the University of Miami Miller School of Medicine. He is past president of the American College of Psychiatrists and the American College of Neuropsychopharmacology. His research has focused on the neurobiology of mood and anxiety disorders with a focus on the long term consequences of child abuse and neglect and how these changes increase vulnerability for psychiatric disorders in adulthood. He has published more than 1000 research reports and reviews, and 15 books. He is a member of the Institute of Medicine of the National Academy of Sciences (USA). The 2022 Edition of Research.com Ranking of Top 1000 Scientists in the field of Medicine ranked Dr. Nemeroff #228 in the world and #153 in the United States.
Dr. Nemeroff has been an ADAA member since 1999, was elected ADAA Chief Medical Officer in March, 2019 and is currently Board President.
Accelerated Theta Burst TMS in the Management of Treatment Resistant Depression
Nolan Williams, MD
Dr. Williams is an Assistant Professor within the Department of Psychiatry and Behavioral Sciences and the Director of the Stanford Brain Stimulation Lab. Dr. Williams has a broad background in clinical neuroscience and is triple board-certified in general neurology, general psychiatry, as well as behavioral neurology & neuropsychiatry. Themes of his work include (a) examining the use of spaced learning theory in the application of neurostimulation techniques, (b) development and mechanistic understanding of rapid-acting antidepressants, and (c) identifying objective biomarkers that predict neuromodulation responses in treatment-resistant neuropsychiatric conditions. He has published papers in high impact peer-reviewed journals including Brain, American Journal of Psychiatry, and the Proceedings of the National Academy of Science. Results from his studies have gained widespread attention in journals such as Science and New England Journal of Medicine Journal Watch as well as in the popular press and have been featured in various news sources including Time, Smithsonian, and Newsweek. Dr. Williams received two NARSAD Young Investigator Awards in 2016 and 2018 along with the 2019 Gerald R. Klerman Award. Dr. Williams received the National Institute of Mental Health Biobehavioral Research Award for Innovative New Scientists in 2020.
Neurosteroid Treatment of Depression
Dr. Robert Lasser, a board-certified psychiatrist with extensive experience in academic medicine, clinical practice, and pharmaceutical industry research, has published 50+ peer-reviewed articles across child, adult, and geriatric mental health topics. Current focus in mood disorders; zuranolone, brexanolone.
After obtaining his BA and MD degrees, Dr. Lasser completed Adult and Geriatric Psychiatry training with research into late-life depression, dementia, and structural neuroimaging, publishing on mood disorders, geriatric psychopharmacology, and dementia biology. Following his transition to industry, Rob held roles of increasing responsibility in operational and medical leadership for neuroscience development and commercialization, having led multiple global programs and product launches at Top-10 pharmaceutical manufacturers as both medical leader and general manager. He has authored protocols, study reports, and regulatory submissions across the development lifecycle. In parallel, Dr. Lasser has maintained clinical practice in geriatric psychotherapy and psychopharmacology, major mental illness, and substance dependence for nearly 20 years. Dr. Lasser added to his formal education by completing an MBA in 2006.
Specialties: Adult Psychiatry, Geriatric Psychiatry (Medical Doctor), Pharmaceutical Development (Pre-NDA, NDA filing, and post-NDA), Pharmaceutical Marketing and Strategy, Formal Business Education with emphasis on Management and Marketing (MBA), Ongoing Clinical Practice(s)
The Metacognitive and Strategic Treatment of OCD + −
The Metacognitive and Strategic Treatment of OCD
Reid Wilson, PhD
This fast-paced training for intermediate and advanced clinicians will teach you the latest innovations of a treatment model that Reid has continually evolved over his 40-year career. Leading from a metacognitive perspective of the disorder, you will learn the step-by-step strategies, supported by paradoxical tactics, in a brief-treatment model for this often-complex disorder.
Reid Wilson, PhD, a Founding Clinical Fellow, served in leadership positions within ADAA for 30 years, including 3 years as Chair of the National Conference and 13 years as a member of the Board of Directors. In 1991, he co-authored with Dr. Edna Foa the first self-help book on ERP for OCD, Stop Obsessing: How to Overcome Your Obsessions and Compulsions. He has received the Jerilyn Ross Clinical Advocate Award from ADAA and the Patricia Perkins Service Award from the International OCD Foundation.